Propylene Glycol Alginate Sodium Sulfate (PSS): The First Oral Heparinoid Marine Drug—A Pharmacological and Clinical Review

Propylene glycol alginate sodium sulfate (PSS) is the first oral heparinoid marine drug, derived from brown algal alginic acid and marketed in 1986. Its core pharmacology, including anticoagulation, lipid-lowering, microcirculation improvement, and neuroprotection, makes it an affordable oral option for chronic ischemic cardiovascular and cerebrovascular diseases. Pharmacological studies have also revealed anti-inflammatory, anti-fibrotic, anti-metastatic, and FGF/FGFR-activating effects. Notably, these activities can be independently modulated by molecular weight and M/G ratio, enabling activity-specific structural optimization, guiding the development of safer derivatives. This review summarizes PSS’s R&D, mechanisms, clinical applications, and safety, aiming to inform precision medication strategies and inspire similar drug development.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Discovery and Pharmacology
Published
2026-11-12
DOI
https://doi.org/10.53941/ijddp.2026.100024
Primary Topic
Seaweed-derived Bioactive Compounds
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Propylene Glycol Alginate Sodium Sulfate (PSS): The First Oral Heparinoid Marine Drug—A Pharmacological and Clinical Review

Xuan Xia, 李佳裕, Guanhua Du, Caixia Hao et al.
International Journal of Drug Discovery and Pharmacology
Seaweed-derived Bioactive Compounds
article

Propylene Glycol Alginate Sodium Sulfate (PSS): The First Oral Heparinoid Marine Drug—A Pharmacological and Clinical Review

Xuan Xia, 李佳裕, Guanhua Du, Caixia Hao, Yupeng Wang, Quancai Li
article en

Abstract

Propylene glycol alginate sodium sulfate (PSS) is the first oral heparinoid marine drug, derived from brown algal alginic acid and marketed in 1986. Its core pharmacology, including anticoagulation, lipid-lowering, microcirculation improvement, and neuroprotection, makes it an affordable oral option for chronic ischemic cardiovascular and cerebrovascular diseases. Pharmacological studies have also revealed anti-inflammatory, anti-fibrotic, anti-metastatic, and FGF/FGFR-activating effects. Notably, these activities can be independently modulated by molecular weight and M/G ratio, enabling activity-specific structural optimization, guiding the development of safer derivatives. This review summarizes PSS’s R&D, mechanisms, clinical applications, and safety, aiming to inform precision medication strategies and inspire similar drug development.

International Journal of Drug Discovery and PharmacologyVol. 5(4)
Peking University (CN), Peking University Third Hospital (CN), Marine Biomedical Research Institute of Qingdao (CN), Ocean University of China (CN)
Good health and well-being
Seaweed-derived Bioactive Compounds
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon